Trial Outcomes & Findings for Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) (NCT NCT04524858)
NCT ID: NCT04524858
Last Updated: 2023-09-21
Results Overview
Recruitment status
TERMINATED
Study phase
PHASE2
Target enrollment
1 participants
Primary outcome timeframe
Baseline up to week 12
Results posted on
2023-09-21
Participant Flow
Participant milestones
| Measure |
ATI-450
Oral, small molecule MK2 inhibitor will be administered twice daily (BID) at a dose of 50 mg
ATI-450: Oral, small molecule MK2 inhibitor
|
|---|---|
|
Overall Study
STARTED
|
1
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
1
|
Reasons for withdrawal
| Measure |
ATI-450
Oral, small molecule MK2 inhibitor will be administered twice daily (BID) at a dose of 50 mg
ATI-450: Oral, small molecule MK2 inhibitor
|
|---|---|
|
Overall Study
Adverse Event
|
1
|
Baseline Characteristics
Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: Baseline up to week 12Population: Due to study termination and only 1 participant being enrolled there are concerns regarding participant confidentiality, therefore no data are being reported.
Outcome measures
Outcome data not reported
Adverse Events
ATI-450
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place